Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3109)
All Articles published online
|
Sep 28, 2005 (publication date) through Jun 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, Dietel M, Denkert C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005; 11(36): 5644-5650 [PMID: 16237758 DOI: 10.3748/wjg.v11.i36.5644] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i36/5644.htm |
| Number | Citing Articles |
| 1 |
Femi Olawale, Opeyemi Iwaloye, Olusola Olalekan Elekofehinti. Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain. Journal of Biomolecular Structure and Dynamics 2022; 40(24): 13606 doi: 10.1080/07391102.2021.1991476
|
| 2 |
Rod K. Nibbe, Sanford Markowitz, Lois Myeroff, Rob Ewing, Mark R. Chance. Discovery and Scoring of Protein Interaction Subnetworks Discriminative of Late Stage Human Colon Cancer. Molecular & Cellular Proteomics 2009; 8(4): 827 doi: 10.1074/mcp.M800428-MCP200
|
| 3 |
N. Stutz, M. Nihal, G.S. Wood. Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma. British Journal of Dermatology 2011; 164(4): 814 doi: 10.1111/j.1365-2133.2010.10128.x
|
| 4 |
Hongyan Li, Leroi V. DeSouza, Shaun Ghanny, Wei Li, Alexander D. Romaschin, Terence J. Colgan, K. W. Michael Siu. Identification of Candidate Biomarker Proteins Released by Human Endometrial and Cervical Cancer Cells Using Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry. Journal of Proteome Research 2007; 6(7): 2615 doi: 10.1021/pr0700798
|
| 5 |
Hiroshi Hirai, Toshiyasu Shimomura, Hideya Komatani, Hidehito Kotani. Novel anti-cancer compounds targeting the cell cycle. Folia Pharmacologica Japonica 2009; 133(1): 27 doi: 10.1254/fpj.133.27
|
| 6 |
Qingqing Wei, Guiyu Zhu, Xinxing Cui, Li Kang, Dingguo Cao, Yunliang Jiang. Expression of CCT6A mRNA in chicken granulosa cells is regulated by progesterone. General and Comparative Endocrinology 2013; 189: 15 doi: 10.1016/j.ygcen.2013.04.019
|
| 7 |
Vânia Diogo, Joana Teixeira, Patrícia M.A. Silva, Hassan Bousbaa. Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives. Clinical Colorectal Cancer 2017; 16(1): 1 doi: 10.1016/j.clcc.2016.06.006
|
| 8 |
Zihan Ran, Wenjie Chen, Jun Shang, Xuemei Li, Zhiyan Nie, Jingcheng Yang, Na Li. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Gene 2019; 721: 144097 doi: 10.1016/j.gene.2019.144097
|
| 9 |
De-Chen Lin, Yu Zhang, Qin-Jing Pan, Hai Yang, Zhi-Zhou Shi, Zhi-Hui Xie, Bo-Shi Wang, Jia-Jie Hao, Tong-Tong Zhang, Xin Xu, Qi-Min Zhan, Ming-Rong Wang. PLK1 Is Transcriptionally Activated by NF-κB during Cell Detachment and Enhances Anoikis Resistance through Inhibiting β-Catenin Degradation in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research 2011; 17(13): 4285 doi: 10.1158/1078-0432.CCR-10-3236
|
| 10 |
Hefei Li, Haibo Wang, Zhenqing Sun, Qiang Guo, Hongyun Shi, Youchao Jia. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Bioscience Reports 2017; 37(4) doi: 10.1042/BSR20170852
|
| 11 |
Nazma Malik, Stefan Vollmer, Sambit Kumar Nanda, Marta Lopez-Pelaez, Alan Prescott, Nathanael Gray, Philip Cohen. Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochemical Journal 2015; 468(3): 363 doi: 10.1042/BJ20141523
|
| 12 |
Ahmad Jalili, Anna Moser, Mikhail Pashenkov, Christine Wagner, Gaurav Pathria, Viola Borgdorff, Melanie Gschaider, Georg Stingl, Sridhar Ramaswamy, Stephan N. Wagner. Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology 2011; 131(9): 1886 doi: 10.1038/jid.2011.136
|
| 13 |
Guillermo de Cárcer. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?. Genes 2019; 10(3): 208 doi: 10.3390/genes10030208
|
| 14 |
David Olmos, Charles Swanton, Johann de Bono. Targeting Polo-Like Kinase: Learning Too Little Too Late?. Journal of Clinical Oncology 2008; 26(34): 5497 doi: 10.1200/JCO.2008.18.6585
|
| 15 |
Karineh Kazazian, Olga Brashavitskaya, Francis S. W. Zih, David Berger-Richardson, Roland S. Z. Xu, Karina Pacholczyk, Jennifer Macmillan, Carol J. Swallow. Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy. Current Colorectal Cancer Reports 2015; 11(4): 187 doi: 10.1007/s11888-015-0275-4
|
| 16 |
Italo Beria, Dario Ballinari, Jay Aaron Bertrand, Daniela Borghi, Roberto Tiberio Bossi, Maria Gabriella Brasca, Paolo Cappella, Michele Caruso, Walter Ceccarelli, Antonella Ciavolella, Cinzia Cristiani, Valter Croci, Anna De Ponti, Gabriele Fachin, Ronald Dale Ferguson, Jacqueline Lansen, Jurgen Karl Moll, Enrico Pesenti, Helena Posteri, Rita Perego, Maurizio Rocchetti, Paola Storici, Daniele Volpi, Barbara Valsasina. Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors. Journal of Medicinal Chemistry 2010; 53(9): 3532 doi: 10.1021/jm901713n
|
| 17 |
Hidenori Imai, Koichi Sugimoto, Yasushi Isobe, Makoto Sasaki, Hajime Yasuda, Kengo Takeuchi, Shinji Nakamura, Yuko Kojima, Junichi Tomomatsu, Kazuo Oshimi. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. International Journal of Hematology 2009; 89(5): 673 doi: 10.1007/s12185-009-0325-2
|
| 18 |
Li Tang, Ting-Ting Wang, Yan-Ting Wu, Cai-Yun Zhou, He-Feng Huang. High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. Fertility and Sterility 2009; 91(4): 979 doi: 10.1016/j.fertnstert.2008.01.041
|
| 19 |
Ding-pei Han, Qian-lin Zhu, Jiang-tao Cui, Pu-xiongzhi Wang, Shun Qu, Qi-feng Cao, Ya-ping Zong, Bo Feng, Min-hua Zheng, Ai-guo Lu. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Medical Science Monitor 2012; 18(6): BR237 doi: 10.12659/MSM.882900
|
| 20 |
V Boni, R Zarate, J C Villa, E Bandrés, M A Gomez, E Maiello, J Garcia-Foncillas, E Aranda. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. The Pharmacogenomics Journal 2011; 11(6): 429 doi: 10.1038/tpj.2010.58
|
| 21 |
Regina Berretta, Pablo Moscato, William C. S. Cho. Cancer Biomarker Discovery: The Entropic Hallmark. PLoS ONE 2010; 5(8): e12262 doi: 10.1371/journal.pone.0012262
|
| 22 |
CHUN XU, SEN LI, TENGFEI CHEN, HAIBO HU, CHENG DING, ZHENLEI XU, JUN CHEN, ZEYI LIU, ZHE LEI, HONG-TAO ZHANG, CHANG LI, JUN ZHAO. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncology Reports 2016; 35(1): 497 doi: 10.3892/or.2015.4392
|
| 23 |
Zhu Qian‐Lin, Wang Ting‐Feng, Cao Qi‐Feng, Zheng Min‐Hua, Lu Ai‐Guo. Inhibition of cytosolic chaperonin CCTζ‐1 expression depletes proliferation of colorectal carcinoma in vitro. Journal of Surgical Oncology 2010; 102(5): 419 doi: 10.1002/jso.21625
|
| 24 |
Poornima Ramkumar, Clement M. Lee, Annie Moradian, Michael J. Sweredoski, Sonja Hess, Andrew D. Sharrocks, Dale S. Haines, E. Premkumar Reddy. JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1. Journal of Biological Chemistry 2015; 290(49): 29617 doi: 10.1074/jbc.M115.664649
|
| 25 |
Zhenfeng Duan, Diana Ji, Edward J. Weinstein, Xianzhe Liu, Michiro Susa, Edwin Choy, Cao Yang, Henry Mankin, Francis J. Hornicek. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Letters 2010; 293(2): 220 doi: 10.1016/j.canlet.2010.01.014
|
| 26 |
Hyungshin Yim, Raymond L. Erikson. Plk1-targeted therapies in TP53- or RAS-mutated cancer. Mutation Research/Reviews in Mutation Research 2014; 761: 31 doi: 10.1016/j.mrrev.2014.02.005
|
| 27 |
Yiting Qiao, Yunxin Pei, Miao Luo, Muthukumar Rajasekaran, Kam M Hui, Jianxiang Chen. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Experimental Biology and Medicine 2021; 246(12): 1343 doi: 10.1177/15353702211008380
|
| 28 |
Elza C. de Bruin, Jan Paul Medema. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treatment Reviews 2008; 34(8): 737 doi: 10.1016/j.ctrv.2008.07.001
|
| 29 |
Benedito A Carneiro, Jessica K Altman, Jason B Kaplan, Gert Ossenkoppele, Ronan Swords, Leonidas C Platanias, Francis J Giles. Targeted therapy of acute myeloid leukemia. Expert Review of Anticancer Therapy 2015; 15(4): 399 doi: 10.1586/14737140.2015.1004316
|
| 30 |
Aiguo Lu, Xiongzhi Wangpu, Dingpei Han, Hao Feng, Jingkun Zhao, Junjun Ma, Shun Qu, Xuehua Chen, Bingya Liu, Minhua Zheng. TXNDC9 Expression in Colorectal Cancer Cells and Its Influence on Colorectal Cancer Prognosis. Cancer Investigation 2012; 30(10): 721 doi: 10.3109/07357907.2012.732160
|
| 31 |
Neil D. Palmisiano, Margaret T. Kasner. Polo‐like kinase and its inhibitors: Ready for the match to start?. American Journal of Hematology 2015; 90(11): 1071 doi: 10.1002/ajh.24177
|
| 32 |
Zhixian Liu, Qingrong Sun, Xiaosheng Wang. PLK1, A Potential Target for Cancer Therapy. Translational Oncology 2017; 10(1): 22 doi: 10.1016/j.tranon.2016.10.003
|
| 33 |
T Ikezoe, J Yang, C Nishioka, Y Takezaki, T Tasaka, K Togitani, H P Koeffler, A Yokoyama. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23(9): 1564 doi: 10.1038/leu.2009.94
|
| 34 |
Meeta P Pradhan, Nagendra KA Prasad, Mathew J Palakal. A systems biology approach to the global analysis of transcription factors in colorectal cancer. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-331
|
| 35 |
Travis L. Schmit, Mark C. Ledesma, Nihal Ahmad. Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention. Pharmaceutical Research 2010; 27(6): 989 doi: 10.1007/s11095-010-0051-8
|
| 36 |
Zheng Fu, Donghua Wen. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis. Cancers 2017; 9(10): 131 doi: 10.3390/cancers9100131
|
| 37 |
Chang-Hyeon Kim, Da-Eun Kim, Dae-Hoon Kim, Ga-Hong Min, Jung-Won Park, Yeo-Bin Kim, Chang K. Sung, Hyungshin Yim. Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis. Experimental & Molecular Medicine 2022; 54(4): 414 doi: 10.1038/s12276-022-00750-y
|
| 38 |
Maria Grazia Cerrito, Emanuela Grassilli. Identifying Novel Actionable Targets in Colon Cancer. Biomedicines 2021; 9(5): 579 doi: 10.3390/biomedicines9050579
|
| 39 |
Lígia C. Gomes-da-Silva, José S. Ramalho, Maria C. Pedroso de Lima, Sérgio Simões, João N. Moreira. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. European Journal of Pharmaceutics and Biopharmaceutics 2013; 85(3): 356 doi: 10.1016/j.ejpb.2013.04.007
|
| 40 |
John C. Burnett, John J. Rossi, Katrin Tiemann. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology Journal 2011; 6(9): 1130 doi: 10.1002/biot.201100054
|
| 41 |
Rajasekhar Chekkara, Naresh Kandakatla, Venkata Reddy Gorla, Sobha Rani Tenkayala, E Susithra. Theoretical studies on benzimidazole and imidazo[1,2-a]pyridine derivatives as Polo-like kinase 1 (Plk1) inhibitors: Pharmacophore modeling, atom-based 3D-QSAR and molecular docking approach. Journal of Saudi Chemical Society 2017; 21: S311 doi: 10.1016/j.jscs.2014.03.007
|
| 42 |
Zhao-Xia Wang, Dong Xue, Zhi-Li Liu, Bin-Bin Lu, Hai-Bo Bian, Xuan Pan, Yong-Mei Yin. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. The International Journal of Biochemistry & Cell Biology 2012; 44(1): 200 doi: 10.1016/j.biocel.2011.10.017
|
| 43 |
Matthew O. Duffey, Tricia J. Vos, Ruth Adams, Jennifer Alley, Justin Anthony, Cynthia Barrett, Indu Bharathan, Douglas Bowman, Nancy J. Bump, Ryan Chau, Courtney Cullis, Denise L. Driscoll, Amy Elder, Nancy Forsyth, Jonathan Frazer, Jianping Guo, Luyi Guo, Marc L. Hyer, David Janowick, Bheemashankar Kulkarni, Su-Jen Lai, Kerri Lasky, Gang Li, Jing Li, Debra Liao, Jeremy Little, Bo Peng, Mark G. Qian, Dominic J. Reynolds, Mansoureh Rezaei, Margaret Porter Scott, Todd B. Sells, Vaishali Shinde, Qiuju Judy Shi, Michael D. Sintchak, Francois Soucy, Kevin T. Sprott, Stephen G. Stroud, Michelle Nestor, Irache Visiers, Gabriel Weatherhead, Yingchun Ye, Natalie D’Amore. Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905). Journal of Medicinal Chemistry 2012; 55(1): 197 doi: 10.1021/jm2011172
|
| 44 |
Claudia Münch, Diana Dragoi, Anna-Verena Frey, Katja Thurig, Michael Lübbert, Ralph Wäsch, Lioudmila Bogatyreva, Dieter Hauschke, Silke Lassmann, Martin Werner, Annette M. May. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research 2015; 39(4): 462 doi: 10.1016/j.leukres.2015.01.007
|
| 45 |
Xin-Yu Zhao, Chun-Lai Nie, Shu-Fang Liang, Zhu Yuan, Hong-Xin Deng, Yu-Quan Wei. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomedicine & Pharmacotherapy 2012; 66(8): 597 doi: 10.1016/j.biopha.2012.01.003
|
| 46 |
T. G. Tut, S. H. S. Lim, I. U. Dissanayake, J. Descallar, W. Chua, W. Ng, P. de Souza, J-S. Shin, C. S. Lee, Kyung S. Lee. Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PLOS ONE 2015; 10(6): e0129313 doi: 10.1371/journal.pone.0129313
|
| 47 |
Lilia Gheghiani, Zheng Fu. The dark side of PLK1: Implications for cancer and genomic instability. Oncotarget 2023; 14(1): 657 doi: 10.18632/oncotarget.28456
|
| 48 |
Hee-Jin Kim, Jung Hee Cho, Jae-Ryong Kim. Downregulation of Polo-Like Kinase 1 Induces Cellular Senescence in Human Primary Cells Through a p53-Dependent Pathway. The Journals of Gerontology: Series A 2013; 68(10): 1145 doi: 10.1093/gerona/glt017
|
| 49 |
Sol‐Bi Shin, Sang‐Uk Woo, Young‐Won Chin, Young‐Joo Jang, Hyungshin Yim. Sensitivity of TP53‐Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity. Journal of Cellular Physiology 2017; 232(10): 2818 doi: 10.1002/jcp.25680
|
| 50 |
Monika Raab, Mourad Sanhaji, Yves Matthess, Albrecht Hörlin, Ioana Lorenz, Christina Dötsch, Nils Habbe, Oliver Waidmann, Elisabeth Kurunci-Csacsko, Ron Firestein, Sven Becker, Klaus Strebhardt. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nature Communications 2018; 9(1) doi: 10.1038/s41467-018-03494-4
|
| 51 |
Georgios Giamas, Yik L. Man, Heidrun Hirner, Joachim Bischof, Klaus Kramer, Kalimullah Khan, Sharmeen S. Lavina Ahmed, Justin Stebbing, Uwe Knippschild. Kinases as targets in the treatment of solid tumors. Cellular Signalling 2010; 22(7): 984 doi: 10.1016/j.cellsig.2010.01.011
|
| 52 |
涛 郭. Recent Research Progress of PLK1 in Malignant Tumors. Advances in Clinical Medicine 2023; 13(02): 2536 doi: 10.12677/ACM.2023.132358
|
| 53 |
Klaus Strebhardt, Axel Ullrich. Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer 2006; 6(4): 321 doi: 10.1038/nrc1841
|
| 54 |
Glen J. Weiss, Gayle Jameson, Daniel D. Von Hoff, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, Alessandro Di Sanzo, Arturo Galvani, Antonella Isacchi, Ramesh K. Ramanathan. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Investigational New Drugs 2018; 36(1): 85 doi: 10.1007/s10637-017-0491-7
|
| 55 |
Melanie Janning, Walter Fiedler. Volasertib for the Treatment of Acute Myeloid Leukemia: A Review of Preclinical and Clinical Development. Future Oncology 2014; 10(7): 1157 doi: 10.2217/fon.14.53
|
| 56 |
Travis L. Schmit, Weixiong Zhong, Vijayasaradhi Setaluri, Vladimir S. Spiegelman, Nihal Ahmad. Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells. Journal of Investigative Dermatology 2009; 129(12): 2843 doi: 10.1038/jid.2009.172
|
| 57 |
Xiaojian Zhang, Kun Liu, Tao Zhang, Zhenlei Wang, Xuan Qin, Xiaoqian Jing, Haoxuan Wu, Xiaopin Ji, Yonggang He, Ren Zhao. Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. Oncotarget 2017; 8(1): 1541 doi: 10.18632/oncotarget.13652
|
| 58 |
Galina Tsykunova, Håkon Reikvam, Aymen Bushra Ahmed, Ina Nepstad, Bjørn Tore Gjertsen, Øystein Bruserud. Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. Expert Opinion on Investigational Drugs 2012; 21(5): 587 doi: 10.1517/13543784.2012.668525
|
| 59 |
Minoru Inoue, Michio Yoshimura, Minoru Kobayashi, Akiyo Morinibu, Satoshi Itasaka, Masahiro Hiraoka, Hiroshi Harada. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. Scientific Reports 2015; 5(1) doi: 10.1038/srep15666
|
| 60 |
Michael J. Bond, Marina Bleiler, Lauren E. Harrison, Eric W. Scocchera, Masako Nakanishi, Narendran G-Dayanan, Santosh Keshipeddy, Daniel W. Rosenberg, Dennis L. Wright, Charles Giardina. Spindle Assembly Disruption and Cancer Cell Apoptosis with a CLTC-Binding Compound. Molecular Cancer Research 2018; 16(9): 1361 doi: 10.1158/1541-7786.MCR-18-0178
|
| 61 |
Marc-Oliver Riener, Thore Thiesler, Claus Hellerbrand, Thomas Amann, Gieri Cathomas, Florian Rudolph Fritzsche, Edgar Dahl, Marcus Bahra, Wilko Weichert, Luigi Terracciano, Glen Kristiansen. Loss of Anterior Gradient-2 expression is an independent prognostic factor in colorectal carcinomas. European Journal of Cancer 2014; 50(10): 1722 doi: 10.1016/j.ejca.2014.04.012
|
| 62 |
Ming-Wen Wang, Zhong Li, Li-Hong Chen, Ning Wang, Jian-Ming Hu, Jin Du, Li-Juan Pang, Yan Qi. Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.917366
|
| 63 |
Ion Cristóbal, Federico Rojo, Juan Madoz-Gúrpide, Jesús García-Foncillas. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Molecular and Cellular Biology 2016; 36(12): 1734 doi: 10.1128/MCB.00130-16
|
| 64 |
Tara R. Rheault, Kelly H. Donaldson, Jennifer G. Badiang-Alberti, Ronda G. Davis-Ward, C. Webb Andrews, Ramesh Bambal, Jeffrey R. Jackson, Mui Cheung. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: Potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties. Bioorganic & Medicinal Chemistry Letters 2010; 20(15): 4587 doi: 10.1016/j.bmcl.2010.06.009
|
| 65 |
Zi-Li He, He Zheng, Hui Lin, Xiong-Ying Miao, De-Wu Zhong. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World Journal of Gastroenterology 2009; 15(33): 4177-4182 doi: 10.3748/wjg.15.4177
|
| 66 |
El Mustapha Bahassi. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. Experimental Biology and Medicine 2011; 236(6): 648 doi: 10.1258/ebm.2011.011011
|
| 67 |
Juan Sun, Peng-Cheng Lv, Feng-Jiao Guo, Xin-Yi Wang, Xiao- Han, Yang Zhang, Gui-Hua Sheng, Shao-Song Qian, Hai-Liang Zhu. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors. European Journal of Medicinal Chemistry 2014; 81: 420 doi: 10.1016/j.ejmech.2014.05.026
|
| 68 |
Ping Zhan, Guang‐min Xi, Bin Zhang, Ying Wu, Hong‐bing Liu, Ya‐fang Liu, Wu‐jian Xu, Qingqing Zhu, Feng Cai, Ze‐jun Zhou, Ying‐ying Miu, Xiao‐xia Wang, Jia‐jia Jin, Qian Li, Tang‐feng Lv, Yong Song. NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma. Journal of Cellular and Molecular Medicine 2017; 21(4): 665 doi: 10.1111/jcmm.13010
|
| 69 |
Yingmei Wang, Ping Ji, Jinsong Liu, Russell R Broaddus, Fengxia Xue, Wei Zhang. Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy. Molecular Cancer 2009; 8(1) doi: 10.1186/1476-4598-8-8
|
| 70 |
Veronika Dill, Johanna Kauschinger, Richard T. Hauch, Lars Buschhorn, Timo O. Odinius, Catharina Müller‐Thomas, Ritu Mishra, Michele C. Kyncl, Burkhard Schmidt, Peter M. Prodinger, Dirk Hempel, Frauke Bellos, Alexander Höllein, Wolfgang Kern, Torsten Haferlach, Julia Slotta‐Huspenina, Florian Bassermann, Christian Peschel, Katharina S. Götze, Irene C. Waizenegger, Ulrike Höckendorf, Philipp J. Jost, Stefanie Jilg. Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis. European Journal of Haematology 2020; 104(2): 125 doi: 10.1111/ejh.13354
|
| 71 |
Norman Ertych, Ailine Stolz, Albrecht Stenzinger, Wilko Weichert, Silke Kaulfuß, Peter Burfeind, Achim Aigner, Linda Wordeman, Holger Bastians. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nature Cell Biology 2014; 16(8): 779 doi: 10.1038/ncb2994
|
| 72 |
Mathias Schmidt, Holger Bastians. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resistance Updates 2007; 10(4-5): 162 doi: 10.1016/j.drup.2007.06.003
|
| 73 |
Michele Caruso, Barbara Valsasina, Dario Ballinari, Jay Bertrand, Maria Gabriella Brasca, Marina Caldarelli, Paolo Cappella, Francesco Fiorentini, Laura M. Gianellini, Alessandra Scolaro, Italo Beria. 5-(2-Amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters 2012; 22(1): 96 doi: 10.1016/j.bmcl.2011.11.065
|
| 74 |
Mao-Wei Cheng, Bing-Chan Wang, Zhi-Qiang Weng, Xiao-Wei Zhu. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochemica 2012; 114(5): 503 doi: 10.1016/j.acthis.2011.09.004
|
| 75 |
Lei Hu, Yan-tao Duan, Jian-fang Li, Li-ping Su, Min Yan, Zheng-gang Zhu, Bing-ya Liu, Qiu-meng Yang. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget 2014; 5(7): 1885 doi: 10.18632/oncotarget.1871
|
| 76 |
Erin Knock, Liyuan Deng, Qing Wu, Daniel Leclerc, Xiao-ling Wang, Rima Rozen. Low Dietary Folate Initiates Intestinal Tumors in Mice, with Altered Expression of G2-M Checkpoint Regulators Polo-Like Kinase 1 and Cell Division Cycle 25c
. Cancer Research 2006; 66(21): 10349 doi: 10.1158/0008-5472.CAN-06-2477
|
| 77 |
Nirmalya Dasgupta, Bhupesh Kumar Thakur, Atri Ta, Sayan Das, George Banik, Santasabuj Das. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis. Biochimica et Biophysica Acta (BBA) - General Subjects 2017; 1861(7): 1777 doi: 10.1016/j.bbagen.2017.03.015
|
| 78 |
Eri Kawata, Eishi Ashihara, Shinya Kimura, Kazumasa Takenaka, Kiyoshi Sato, Ruriko Tanaka, Asumi Yokota, Yuri Kamitsuji, Miki Takeuchi, Junya Kuroda, Fumihiro Tanaka, Toshikazu Yoshikawa, Taira Maekawa. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Molecular Cancer Therapeutics 2008; 7(9): 2904 doi: 10.1158/1535-7163.MCT-08-0473
|
| 79 |
Sol-Bi Shin, Sang-Uk Woo, Hyungshin Yim. Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer. Therapeutic Advances in Medical Oncology 2019; 11: 175883591984637 doi: 10.1177/1758835919846375
|